Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C K Lippincott

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|April 4, 2019
Discordant rifampicin susceptibility results are associated with Xpert<sup>®</sup> MTB/RIF probe B and probe binding delayR H Berhanu, K Schnippel, R Kularatne, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|July 12, 2018
Can patients afford the cost of treatment for multidrug-resistant tuberculosis in Ethiopia?R H Berhanu, K Schnippel, R Kularatne, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|February 17, 2015
The complexities of Xpert® MTB/RIF interpretationC K Lippincott, M B Miller, A Van Rie, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|April 4, 2019
Discordant rifampicin susceptibility results are associated with Xpert<sup>®</sup> MTB/RIF probe B and probe binding delayR H Berhanu, K Schnippel, R Kularatne, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|July 12, 2018
Can patients afford the cost of treatment for multidrug-resistant tuberculosis in Ethiopia?R H Berhanu, K Schnippel, R Kularatne, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|February 17, 2015
The complexities of Xpert® MTB/RIF interpretationC K Lippincott, M B Miller, A Van Rie, et al.
Pageof 1